Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,000 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control 2: Standard of Care Clear all
Recruiting Phase 3 Interventional

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

NCT06650579
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix
Drug · Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 3 Interventional Results available

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

NCT05891496
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Sun City, Arizona • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Recruiting Not applicable Interventional

Biologic Injection For Adults With Lumbar Disc Herniation

NCT07386548
View directory record Official record
Conditions
Degenerative Disc Disease, DDD, Degenerative Disc Disease Lumbar, Degenerative Disc Disease, Lumbar, Lumbar Disc Herniation, Disc Herniation, Lumbar, Bone Marrow Aspirate Concentrate, Intervertebral Disc Displacement, Low Back Pain, Chronic Low Back Pain (CLBP), CLBP - Chronic Low Back Pain
Interventions
Bone Marrow Aspirate Concentrate (BMAC)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 1 Interventional

Intervention for Reduced Sound Tolerance

NCT00890526
View directory record Official record
Conditions
Hyperacusis
Interventions
Sound Therapy (Tinnitus Retraining Therapy), Counseling (Tinnitus Retraining Therapy), No Counseling, Placebo Sound Therapy
Other
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

NCT04130204
View directory record Official record
Conditions
Gout
Interventions
DYV700, Placebo, Colchicine 0.6 mg
Drug
Lead sponsor
Dyve Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Poway, California
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 5, 2026, 5:12 PM EDT
Recruiting Phase 4 Interventional

Diabetes in African Youth

NCT05454176
View directory record Official record
Conditions
type1diabetes
Interventions
Libre 2, Device for SMBG and Libre Pro
Device
Lead sponsor
University of Minnesota
Other
Eligibility
4 Years to 26 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
19
States / cities
Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 5, 2026, 5:12 PM EDT
Withdrawn Not applicable Interventional

Taking POSNA's OrthoKids to the People

NCT04996745
View directory record Official record
Conditions
Fracture Forearm, Pediatric ALL
Interventions
Tablet-based educational intervention
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
0 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)

NCT02674464
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Provider Audit-Feedback, Stratified by Race and Ethnicity, Blood Pressure Measurement Standardization, System Level Leadership Intervention, Collaborative Care Team Intervention, Community Health Worker Referral, Specialist Care Consultation
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 100 Years
Enrollment
1,820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Mobility and Outcomes After Cardiac Surgery

NCT03806257
View directory record Official record
Conditions
Cardiac Rehabilitation
Interventions
Enhanced Physical Therapy Protocol
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 5, 2026, 5:12 PM EDT
Recruiting Not applicable Interventional

Arrhythmia Detection After MI

NCT05073419
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Standard of Care, ICM Implantation
Other · Device
Lead sponsor
Samir Saba
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional

The Effects of Journaling on Health-Related Mood and Clinical Outcomes in Post-MI Patients

NCT02481544
View directory record Official record
Conditions
Myocardial Infarction, Psychosocial Factors
Interventions
Gratitude Journaling Plus SOC, Memorable Events Journaling Plus SOC
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
35 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cessation Clinical Trial

NCT06806098
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Truth Initiative Digital Cessation Program, Usual Care
Behavioral
Lead sponsor
Truth Initiative
Other
Eligibility
18 Years and older
Enrollment
1,555 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional Results available

Nanodiamond Modified Gutta Percha (NDGP) Composite for Non-surgical Root Canal Therapy (RCT) Filler Material

NCT02698163
View directory record Official record
Conditions
Dental Pulp Diseases, Dental Pulp Necrosis, Nerve Root Pain Nec
Interventions
Nanodiamond reinforced Gutta Percha, Gutta Percha
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Not applicable Interventional

Physical Therapy vs Remote Exercise for Knee Pain Due to Osteoarthritis (OA)

NCT06167304
View directory record Official record
Conditions
Knee Osteoarthritis, Chronic Pain
Interventions
Technology-implemented exercise therapy, Traditional Physical Therapy
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19)

NCT05236270
View directory record Official record
Conditions
COVID-19, Vaccine Refusal
Interventions
Text Message, Motivational Interviewing, Electronic Educational Message with Tailored Questions/Prompts
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 100 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT04564339
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions
Ravulizumab, Placebo, Background Therapy
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
San Dimas, California • Santa Monica, California • South Gate, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 5, 2026, 5:12 PM EDT
Not listed No phase listed Observational

Expressive Disclosure and Colorectal Cancer

NCT00853203
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Interviews, Questionnaires, Electronically Activated Recorder (EAR), Group Meetings, Written Materials
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 5, 2026, 5:12 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of a Technology-Based Intervention on Weight Change Post-Bariatric Surgery

NCT02867696
View directory record Official record
Conditions
Motor Activity, Weight Loss
Interventions
Standard Care, Technology-based Intervention (TECH)
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 4 Interventional Results available

Comparing Effectiveness of CSE Versus DPE for Labor Analgesia

NCT05068661
View directory record Official record
Conditions
Labor Pain
Interventions
Ropivacaine 0.1% Injectable Solution, Bupivacaine 0.25% Injectable Solution
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 5, 2026, 5:12 PM EDT
Recruiting Early Phase 1 Interventional

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

NCT04469842
View directory record Official record
Conditions
Lung Transplant; Complications
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 5, 2026, 5:12 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 5, 2026, 5:12 PM EDT
Active, not recruiting Phase 3 Interventional

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 5, 2026, 5:12 PM EDT